BioWorld

June 18, 2003

MedImmune's Intranasal Vaccine FluMist Receives FDA Approval

MedImmune Inc. received long-awaited news late Tuesday afternoon as the FDA approved FluMist, a nasally delivered product that has ridden a rocky road throughout the regulatory review process. (BioWorld Today) Read More

Cell Therapeutics, Novuspharma Merging In $236M Stock Exchange

Alcohol Abuse In Pregnancy Can Bring On Fetal Alcohol Syndrome, Mental Retardation In The Young

Biomira, Merck KGaA Report Failed Theratope Phase III Trial

BioMarin Aiming To Raise $125M In Convertible Notes

Questcor Raises $5M To Fund $18.2M Purchase Of Nascobal

Boston Life Sciences Plans Another Altropane Phase III

Amylin Sends Symlin Amendment To FDA, Seeks $150M In Notes

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for July 10, 2026.

3D rendering of an antibody drug conjugate

‘Target-high but uptake-defective’ state identified in ADC resistance

BioWorld

Separate research teams have reported new insights into resistance mechanisms to the antibody-drug conjugate (ADC) Padcev (enfortumab vedotin, Astellas Pharma...

Ionis, AZ shares down on unexpected Wainua flop in cardiomyopathy

BioWorld

News of the unexpected phase III failure of the gene silencing drug Wainua (eplontersen) in the treatment of transthyretin-mediated amyloid cardiomyopathy sent...

FENS 2026: Shedding light on the sheddome

BioWorld

At the recently opened FENS Forum 2026 in Barcelona – the Federation of European Neuroscience Societies’ flagship congress and Europe’s largest neuroscience...

FENS 2026: Next-gen biologics take on brain disease

BioWorld

Whether by fine-tuning neurotransmitter signaling or silencing disease-associated genes, emerging biologic therapies are reshaping neuroscience drug development,...